返回 
加入收藏
银杏叶提取物制剂序贯疗法治疗老年急性脑梗死的临床研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 银杏叶提取物制剂序贯疗法治疗老年急性脑梗死的临床研究 |
| TITLE： | |
| 摘要： | 目的：观察银杏叶提取物制剂序贯疗法治疗老年急性脑梗死的临床效果和安全性，并进行药物经济学评价。方法：选取2014年8月－2015年8月我院神经内科收治的急性脑梗死患者98例，按随机数字表法分为对照组和试验组，各49例。两组患者均进行抗血小板聚集、改善微循环等常规治疗；对照组患者在常规治疗基础上给予舒血宁注射液10 mL，ivgtt，qd，连用21 d；试验组患者在常规治疗基础上给予舒血宁注射液10 mL，ivgtt，qd，7～10 d后停用，改用银杏叶片1片，po，tid，累计用药21 d。比较两组患者的临床疗效，治疗前后的欧洲脑卒中量表（ESS）评分、日常生活活动能力量表（ADL）评分、血液流变学指标和血脂指标，以及不良反应发生情况，并用最小成本分析法进行药物经济学评价。结果：治疗后，对照组、试验组患者的总有效率分别为87.23％、83.33％，两组比较差异无统计学意义（P＞0.05）。治疗前，两组患者的ESS评分、ADL评分、血液流变学和血脂指标比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者的ESS和ADL评分均明显升高，全血黏度、血浆黏度、血细胞比容、纤维蛋白原含量、TC和TG均明显降低，与治疗前比较差异均有统计学意义（P＜0.05），但组间比较差异均无统计学意义 （P＞0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。对照组和试验组的平均治疗成本分别为（7 060.9±234.8）元和（5 800.7±149.5）元，差异有统计学意义（P＜0.01）。结论：银杏叶提取物制剂序贯疗法与静脉滴注给药治疗老年急性脑梗死的疗效、安全性相当，但序贯疗法更具经济学优势。 |
| ABSTRACT： | OBJECTIVE： To observe clinical effects and safety of sequential therapy of Ginkgo biloba extract preparation for elderly acute cerebral infarction， and to evaluate its pharmacoeconomics. METHODS： Totally 98 patients with acute cerebral infarction selected from neurology department of our hospital during Aug. 2014-Aug. 2015 were divided into control group and test group according to random number table， with 49 cases in each group. Both groups received routine therapy of antiplatelet aggregation， microcirculation improvement. Control group was additionally given Shuxuening injection 10 mL， ivgtt， qd， for consecutive 21 d. Test group was additionally given Shuxuening injection 10 mL， ivgtt， qd， for 7-10 d； and then given G. biloba tablet instead， 1 tablet， po ， tid， for 21 d in total. Clinical efficacies of 2 groups were compared as well as ESS score， ADL score， blood flow indexes and blood lipid indexes before and after treatment， and adverse drug reaction. Cost-minimization analysis was used for pharmacoeconomic evaluation. RESULTS： After treatment， total response rate of control group and test groups were 87.23％ and 83.33％， without statistical significance （P＞0.05）. Before treatment， there was no statistical significance in ESS score， ADL score， blood flow indexes and blood lipid indexes between 2 groups （P＞0.05）. After treatment， ESS score and ADL score of 2 groups were increased significantly， and whole blood viscosity， plasma viscosity， hematocrit， fibrinogen content， TC and TG were decreased significantly； there was statistical significance with before treatment （P＜0.05）； there was no statistical significance between 2 groups （P＞0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. The average cost of control group and test group were （7 060.9±234.8） yuan and （5 800.7±149.5） yuan， with statistical significance （P＜0.01）. CONCLUSIONS： The sequential therapy of G. biloba extract preparation is similar to intravenous dirpping in the treatment of elderly acute cerebral infarction in therapeutic efficacy and safety. The sequential therapy is better in economics field. |
| 期刊： | 2017年第28卷第11期 |
| 作者： | 董维森，李洁，陈赫军，何芳，崔永建 |
| AUTHORS： | DONG Weisen，LI Jie，CHEN Hejun，HE Fang，CUI Yongjian |
| 关键字： | 急性脑梗死；老年患者；银杏叶提取物；序贯疗法；药物经济学 |
| KEYWORDS： | Acute cerebral infarction； Elderly patients； Ginkgo biloba extract； Sequential therapy； Pharmacoeconomics |
| 阅读数： | 178 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
